Avandia :: FDA Advisory Panel supports Glaxo’s diabetes drug Avandia
GlaxoSmithKline [NYSE: GSK] welcomed the nearly unanimous recommendation of an U.S. Food and Drug Administration?s (FDA) advisory committee to support Avandia?s (rosiglitazone maleate) continued availability to patients in the US.